Business Wire

Insight Launches Insight AI, a New Way to Achieve AI Outcomes

12.11.2025 15:00:00 CET | Business Wire | Press Release

Share

Insight Enterprises (NASDAQ: NSIT) today announced the launch of Insight AI, a comprehensive suite of services and expertise designed to address the most common barriers to value realisation. Insight AI offers clients a pragmatic approach — a clear roadmap from ideation to ROI — with the expertise, the tools, and the delivery engine clients need to get beyond vision and experimentation.

“We’re not new to AI — but we are introducing a new way to execute with AI,” said Joyce Mullen, President and CEO, Insight. “After helping clients across industries navigate AI and as we transform our own business from the inside out, we’ve learned what matters when starting an AI journey. For example, we’ve created an AI tool to simplify the discovery process of an engagement, saving clients money and getting to value faster. And Inspire11 — our most recent acquisition — has proprietary processes that make this even more meaningful, ensuring success is measured by client outcomes.”

Insight AI is purpose-built to eliminate the traditional bottlenecks of enterprise AI — high costs, long timelines, and misalignment with business priorities. Unlike traditional consulting engagements, Insight AI uses intelligent tooling and pre-built accelerators to give clients a strategic head start alongside proof of value from day zero.

This strategic approach combines significant capital investment, the deep technical and business expertise gained through the acquisitions of NWT, Amdaris, and most recently Inspire11, and Insight's own experience in applying AI to its internal operations—re-engineering processes, reskilling teams, and aligning technology investments directly with business value. This powerful combination translates into a client-ready methodology that helps organisations build pragmatic roadmaps, accelerate time-to-value, and achieve a clear return on their AI investments.

Acceleration through Rapid AI

At the heart of the new practice is Rapid AI, Insight's accelerated methodology that helps organisations move from AI ideation to a working proof-of-concept in 5 business days or less.

  • This low-risk, high-impact programme addresses common business challenges, including "discovery fatigue" and investment uncertainty.
  • The Rapid AI approach provides the clarity and data-driven evidence needed to secure stakeholder alignment and validate ROI.
  • By delivering a demonstrable AI prototype and a strategic path to full-scale deployment, it ensures that AI initiatives are primed for successful implementation.

“Our Rapid AI approach starts with deeply understanding the business challenges and opportunities,” said Adrian Gregory, President Insight EMEA. “We then get to work fast with Forward Deployed Engineers building rapid solutions ready to go into production build. This opens up a new way of thinking about business and the possibilities to better connect with clients, drive intelligent growth, be more efficient and get there more quickly."

“Partnering with Amdaris, an Insight company, has accelerated our AI journey and transformed our operations,” said Chris Standeven, Managing Director, FirstPoint Logistics. “Together we’ve implemented agentic Conversational AI that now manages supplier and driver communications - chasing updates, resolving issues, and onboarding new suppliers. It’s reduced our team’s workload by around 30%, allowing us to focus on service excellence.

“We’ve also introduced AI-powered Dynamic Pricing, which automatically calculates optimal job rates based on live factors like distance, demand, and availability. This gives our customers more accurate, fair pricing and helps them save money while improving efficiency across the board. Amdaris/Insight have been a true partner - combining deep technical expertise with a clear understanding of how AI can create real impact in offering service excellence for our client base.”

Addressing EMEA Adoption Gap

According to Insight’s newly released EMEA AI Report, 71 per cent of organisations across the region remain stalled in pilot or experimental AI phases, struggling to convert potential into true competitive advantage. While confidence in autonomous AI is on the rise—57 per cent of organisations now report being “very confident” in its reliability—proof-of-concept projects alone are not enough to reshape the business landscape.

Insight AI directly tackles this execution gap by uniting the following elements into one integrated framework designed for measurable ROI:

  • Strategic advisory
  • AI-forward engineering
  • Delivery accelerators

“AI is no longer just a competitive advantage—it’s becoming a competitive necessity,” said Adrian Gregory, President Insight EMEA. “The organisations that win will be those that can connect vision to value quickly and responsibly. Insight AI helps them do exactly that.”

To learn more about Insight AI in EMEA, visit here.

About Insight

Insight Enterprises is a leading Solutions Integrator that helps clients solve technology challenges by combining the right hardware, software, and services. We’re a global Fortune 500 technology company with a network of over 6,000 partners and experts around the world who provide access to end-to-end IT capabilities. For more than 35 years, we have delivered and optimized technology solutions for our clients efficiently, effectively, and safely. We are rated as a Great Place to Work, a Forbes World’s Best Employer, and a Fortune World’s Best Workplace. Discover more at insight.com. NSIT-M

View source version on businesswire.com: https://www.businesswire.com/news/home/20251112795319/en/

Contacts

Media Contacts
Melissa John
Insight
Tel. 07342716154
Email: melissa.john@insight.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye